Advances in biopharma chromatography technology

New recombinant protein A affinity chromatography resin responds to the industry’s need for greater efficiency in monoclonal antibodies (mAbs) processing, helping to bring life-changing therapies to market faster.

Biopharma researcher in lab

J.T.Baker® BAKERBOND® PROchievA
Recombinant protein A affinity chromatography resin

J.T.Baker® BAKERBOND® PROchievA
Recombinant protein A affinity chromatography resin

According to a National Center for Biotechnology Information publication, protein A chromatography is a proven downstream purification process in commercializing mAbs. Yet there remains a need to reduce the total purification steps while improving purity and yield.

PROchievA resins The BAKERBOND® PROchievA affinity chromatography resin offers a new process choice to biopharmaceutical manufacturers in the first chromatography step of mAbs production, without disrupting production workflow processes or protocols.

Avantor® developed the BAKERBOND® PROchievA resin to address key industry needs in the following ways:

  • The new resin uses a novel, proprietary ligand to provide best-in-class purification in critical protein A chromatography step of mAbs manufacturing
  • BAKERBOND® PROchievA resin has shown excellent dynamic binding capacity for mAbs in performance tests conducted against comparable protein A resins on the market today
  • It has demonstrated improved purification results in emerging, complex molecules, such as Fc-Fusion proteins and similar IgG antibody-like molecules
  • The resin’s particle size and porous yet rigid nature of agarose base allows for higher flow, resulting in higher efficiency in downstream processing
J.T.Baker® BAKERBOND® PROchievA recombinant protein A affinity chromatography resin

I am interested in learning more details about Avantor’s new BAKERBOND® PROchievA resin.

Improved supply chain security and performance

With the BAKERBOND® PROchievA resin, Avantor ensures an independent chromatography resin supply alternative to existing purification products is commercially available, providing greater supply chain flexibility and security along with purification that demonstrates best-in-class performance.

In several applications, the BAKERBOND® PROchievA resin was shown to deliver higher levels of protein purity post-protein A chromatography, thus reducing the burden on subsequent purification operations. These include several examples in the emerging market for Fc-Fusion proteins (Fig.1).

Fc-Fusion protein study comparison

The new resin enhances Avantor’s J.T.Baker® family of products for biopharmaceutical research and production. Avantor’s J.T.Baker® brand chromatography products allow biopharma manufacturers to realize higher production efficiencies, meet stringent regulatory requirements and accelerate regulatory approval in bringing new therapies to market.

LEARN MORE ABOUT THE FULL RANGE OF AVANTOR BIOPROCESSING CAPABILITIES.